Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00452387 is registered in ClinicalTrials.gov with Accelerated Community Oncology Research Network as lead sponsor.

NCT NCT00452387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00452387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
Lead sponsor
Accelerated Community Oncology Research Network
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2007
Completion date
January 31, 2009
Enrollment
22 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer